Home Stock

Stock Research: Hanmi Pharmaceutical

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Hanmi Pharmaceutical

KSC:128940 KR7128940004
49
  • Value
    16
  • Growth
    75
  • Safety
    Safety
    27
  • Combined
    23
  • Sentiment
    96
  • 360° View
    360° View
    49
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Hanmi Pharm Co Ltd manufactures and sells pharmaceuticals. It operates in the pharmaceuticals and materials processing industries, and exports its products. In the last fiscal year, the company had a market cap of $2,625 million, profits of $553 million, and revenue of $1,013 million. There is no data for the number of employees.

more

ANALYSIS: With an Obermatt 360° View of 49 (better than 49% compared with alternatives), overall professional sentiment and financial characteristics for the stock Hanmi Pharmaceutical are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Hanmi Pharmaceutical. The consolidated Growth Rank has a good rank of 75, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 75% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 96, which means that professional investors are more optimistic about the stock than for 96% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 16, which means that the share price of Hanmi Pharmaceutical is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 84% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 27, which means that the company has a financing structure that is riskier than those of 73% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Price vs. Book (P/B)
Weakest Rank Stock Returns
Country South Korea
Industry Pharmaceuticals
Size Medium
Website hanmi.co.kr
Index
KOSPI
Hanmi Pharmaceutical stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
16 16 14 15
Growth
75 72 91 91
Safety
Safety
27 10 10 1
Sentiment
96 72 96 39
360° View
360° View
49 10 49 15
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
71 81 67 76
Opinions Change
76 32 75 42
Pro Holdings
n/a 70 74 12
Market Pulse
53 63 72 56
Sentiment
96 72 96 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
16 16 14 15
Growth
75 72 91 91
Safety Safety
27 10 10 1
Combined
23 1 27 18
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
22 28 30 39
Price vs. Earnings (P/E)
24 30 26 14
Price vs. Book (P/B)
8 19 12 14
Dividend Yield
61 20 22 17
Value
16 16 14 15
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
57 61 61 52
Profit Growth
77 56 85 100
Capital Growth
16 90 75 88
Stock Returns
99 28 63 27
Growth
75 72 91 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
44 23 9 2
Refinancing
10 14 9 5
Liquidity
63 75 28 16
Safety Safety
27 10 10 1

Similar Stocks

Discover high‑ranked alternatives to Hanmi Pharmaceutical and broaden your portfolio horizons.

Daiwa House

TYO:1925
Country: Japan
Industry: Electric Utilities
Size: XX-Large
Full Stock Analysis

Kinden

TYO:1944
Country: Japan
Industry: Construction & Engineering
Size: X-Large
Full Stock Analysis

Shionogi

TYO:4507
Country: Japan
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

Youngone

KSC:111770
Country: South Korea
Industry: Apparel, Accessories, Luxury
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a classic, high-risk growth play: high growth and positive sentiment outweigh low Value Rank (expensive) and risky financing. This is for aggressive growth investors who are comfortable with the high price and risk, believing the growth story justifies the expense.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews